{"filing":{"accession_number":"0001193125-26-267659","cik":"0001680581","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"fulc-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/fulc-20260605.htm"},"events":[{"id":5369,"run_id":4703,"accession_number":"0001193125-26-267659","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing's primary focus is the approval of cash retention payments and amended \"Change in Control\" benefits for named executives (Sapir, Oltmans, Musso) in connection with a restructuring plan following discontinuation of pociredir development. While the section also discloses Greg Tourangeau's departure, the bulk of the disclosure centers on compensatory arrangements—retention bonuses and severance modifications—approved by the compensation committee and board, making exec_compensation the most salient event type.","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6344,"accession_number":"0001193125-26-267659","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing's primary focus is the approval of cash retention payments and amended \"Change in Control\" benefits for named executives (Sapir, Oltmans, Musso) in connection with a restructuring plan following discontinuation of pociredir development. While the section also discloses Greg Tourangeau's departure, the bulk of the disclosure centers on compensatory arrangements—retention bonuses and severance modifications—approved by the compensation committee and board, making exec_compensation the most salient event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:31:20.417176+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6344,"accession_number":"0001193125-26-267659","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing's primary focus is the approval of cash retention payments and amended \"Change in Control\" benefits for named executives (Sapir, Oltmans, Musso) in connection with a restructuring plan following discontinuation of pociredir development. While the section also discloses Greg Tourangeau's departure, the bulk of the disclosure centers on compensatory arrangements—retention bonuses and severance modifications—approved by the compensation committee and board, making exec_compensation the most salient event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:31:20.417176+00:00","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-11"}]}